Tokyo Tape
Sign in
← Kubota Pharmaceutical Holdings

Quarterly report · Q3

4596.TEDINET S100PKP9
Period2022-01-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 57
MetricValuePeriodScopeSource row
Revenue¥3m2022-01-01 → 2022-09-30Cons.Revenue IFRS (5-year summary)
Operating income−¥1.7bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income−¥481m2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income−¥1.9bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income−¥573m2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax−¥1.7bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥484m2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax−¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥580m2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥1.7bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥484m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥580m2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥1.7bn2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income−¥484m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income−¥580m2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥4.7bnat 2022-09-30Cons.Assets IFRS
Total assets¥4.8bnat 2021-12-31Cons.Assets IFRS
Total assets¥5.4bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥623mat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥680mat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥4.1bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥4.2bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥4.7bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥6.0bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥4.1bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥4.2bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥4.7bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥4.4bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥4.0bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥4.5bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥2.5bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.7bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥2.5bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥1.9bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥566m2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥3.6bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥3.5bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥1.2bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥171m2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥210m2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-35.22022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-9.452022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥-57.462021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-42.52021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-12.662021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-35.22022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-9.452022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-57.462021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-42.52021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-12.662021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio86.8%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio85.9%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio88.3%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 434
ItemContextValueUnit
Accrued liabilities ope cf IFRSPrior1YTDDuration-6162000JPY
Accrued liabilities ope cf IFRSCurrentYTDDuration-89560000JPY
Accrued compensation ope cf IFRSPrior1YTDDuration-17274000JPY
Accrued compensation ope cf IFRSCurrentYTDDuration-27154000JPY
Deferred rent and lease incentives ope cf IFRSPrior1YTDDuration－JPY
Deferred rent and lease incentives ope cf IFRSCurrentYTDDuration-11849000JPY
Other assets ope cf IFRSPrior1YTDDuration10723000JPY
Other assets ope cf IFRSCurrentYTDDuration8757000JPY
Subtotal ope cf IFRSPrior1YTDDuration-1911625000JPY
Subtotal ope cf IFRSCurrentYTDDuration-1669845000JPY
Interest paid ope cf IFRSPrior1YTDDuration-14308000JPY
Interest paid ope cf IFRSCurrentYTDDuration-8776000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration-1925933000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration-1678621000JPY
Interest received inv cf IFRSPrior1YTDDuration16658000JPY
Interest received inv cf IFRSCurrentYTDDuration9000000JPY
Purchase of other financial assets inv cf IFRSPrior1YTDDuration-394378000JPY
Purchase of other financial assets inv cf IFRSCurrentYTDDuration-581342000JPY
Maturities of marketable securities available for sale inv cf IFRSPrior1YTDDuration3813038000JPY
Maturities of marketable securities available for sale inv cf IFRSCurrentYTDDuration1102520000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-8272000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-1646000JPY
Collection of lease receivable inv cf IFRSPrior1YTDDuration98718000JPY
Collection of lease receivable inv cf IFRSCurrentYTDDuration24954000JPY
Proceeds from collection of leasehold deposits and guarantee deposits inv cf IFRSPrior1YTDDuration－JPY
Proceeds from collection of leasehold deposits and guarantee deposits inv cf IFRSCurrentYTDDuration12598000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration3525764000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration566084000JPY
Proceeds from issuance of common stock fin cf IFRSPrior1YTDDuration319898000JPY
Proceeds from issuance of common stock fin cf IFRSCurrentYTDDuration1212454000JPY
Proceeds from issuance of share acquisition rights fin cf IFRSPrior1YTDDuration－JPY
Proceeds from issuance of share acquisition rights fin cf IFRSCurrentYTDDuration3100000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-109790000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-54922000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration210108000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration1160632000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration154413000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration347239000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration1964352000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration395334000JPY
Cash and cash equivalents IFRSPrior2YearInstant2533786000JPY
Cash and cash equivalents IFRSPrior1YearInstant3977312000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant4498138000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant4372646000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-11-11
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第８期第３四半期（自　2022年７月１日　至　2022年９月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)窪田製薬ホールディングス株式会社

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass